Neurocrine Biosciences
NBIX
419 hedge funds and large institutions have $9.23B invested in Neurocrine Biosciences in 2021 Q1 according to their latest regulatory filings, with 77 funds opening new positions, 161 increasing their positions, 127 reducing their positions, and 60 closing their positions.
33% more call options, than puts
Call options by funds: $69.4M | Put options by funds: $52.1M
28% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 60
27% more repeat investments, than reductions
Existing positions increased: 161 | Existing positions reduced: 127
7% more capital invested
Capital invested by funds: $8.6B → $9.23B (+$636M)
5.45% more ownership
Funds ownership: 95.84% → 101.28% (+5.4%)
3% more funds holding
Funds holding: 405 → 419 (+14)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$419M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$111M |
| 3 |
State Street
Boston,
Massachusetts
|
+$82.8M |
| 4 |
Bank of New York Mellon
New York
|
+$79.7M |
| 5 |
DM
Deerfield Management
New York
|
+$76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$193M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$132M |
| 3 |
PA
Perceptive Advisors
New York
|
-$100M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$58.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$52.3M |
NBIX Hedge Fund Activity: Q1 2021 in Review
419 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2021, worth a combined $9.23B — up 7.4% from $8.6B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new NBIX positions and 60 closed out — a net gain of 17 holders — while 161 added to existing stakes and 127 trimmed.
The largest buyer was BlackRock, adding an estimated $419M. The largest seller was Capital International Investors, cutting an estimated $193M.
- 419 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2021, up from 405 in Q4 2020.
- Funds reported $9.23B of Neurocrine Biosciences stock for Q1 2021, up 7.4% quarter-over-quarter.
- 77 funds opened new Neurocrine Biosciences positions in Q1 2021 and 60 closed out, a net change of +17 holders.
- The largest Neurocrine Biosciences buyer in Q1 2021 was BlackRock, an estimated $419M added.
- The largest Neurocrine Biosciences seller in Q1 2021 was Capital International Investors, an estimated $193M sold.
Based on aggregated 13F filings for Q1 2021.